A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
The study was prematurely discontinued on 04-May-2018 due to slow enrollment that would preclude obtaining study results in a timely manner.
Key Inclusion Criteria:
Key Exclusion Criteria:
CABA, Buenos Aires 1407, Argentina
CABA, Buenos Aires C1056ABJ, Argentina
CABA, Buenos Aires F.D. C1179AAB, Argentina
Lennik, Brussels Capital 1070, Belgium
Wilton, Cork, Ireland
County Limerick, V94 F858, Ireland
Loerenskog, NO 1478, Norway
Bundang Gu, Gyeonggi-do 13620, South Korea